GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Shiller PE Ratio

Medexus Pharmaceuticals (TSX:MDP) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medexus Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Medexus Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Shiller PE Ratio Chart

Medexus Pharmaceuticals Annual Data
Trend Dec13 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Medexus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Medexus Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Shiller PE Ratio falls into.



Medexus Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Medexus Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Medexus Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.027/125.4675*125.4675
=-0.027

Current CPI (Dec. 2023) = 125.4675.

Medexus Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -1.199 96.945 -1.552
201406 -0.152 99.473 -0.192
201409 -0.296 99.394 -0.374
201412 -0.298 98.367 -0.380
201503 -0.393 99.789 -0.494
201506 -0.299 100.500 -0.373
201509 -0.148 100.421 -0.185
201512 -0.296 99.947 -0.372
201603 0.226 101.054 0.281
201606 0.299 102.002 0.368
201609 -0.179 101.765 -0.221
201612 -0.149 101.449 -0.184
201703 -0.227 102.634 -0.278
201706 -0.215 103.029 -0.262
201709 -0.059 103.345 -0.072
201712 -0.173 103.345 -0.210
201803 -0.168 105.004 -0.201
201806 -0.120 105.557 -0.143
201809 -0.625 105.636 -0.742
201812 -0.099 105.399 -0.118
201903 0.027 106.979 0.032
201906 -0.152 107.690 -0.177
201909 0.040 107.611 0.047
201912 -0.192 107.769 -0.224
202003 -0.161 107.927 -0.187
202006 -0.325 108.401 -0.376
202009 -0.146 108.164 -0.169
202012 -1.127 108.559 -1.303
202103 -0.792 110.298 -0.901
202106 -0.415 111.720 -0.466
202109 0.659 112.905 0.732
202112 -0.090 113.774 -0.099
202203 -0.342 117.646 -0.365
202206 -0.090 120.806 -0.093
202209 -0.187 120.648 -0.194
202212 -0.095 120.964 -0.099
202303 0.465 122.702 0.475
202306 0.040 124.203 0.040
202309 -0.068 125.230 -0.068
202312 -0.027 125.468 -0.027

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medexus Pharmaceuticals  (TSX:MDP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Medexus Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals (TSX:MDP) Business Description

Traded in Other Exchanges
Address
35 Nixon Road, Suite 1, Bolton, ON, CAN, L7E 1K1
Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.